Quadrant Capital Group LLC Purchases 9,491 Shares of Becton, Dickinson and Company $BDX

Key Points

• Quadrant Capital Group LLC raised its stake in Becton, Dickinson & Company by 152.3%, buying 9,491 shares to hold 15,724 shares valued at about $2.94 million after the 3rd quarter.
• Becton, Dickinson beat quarterly expectations with $2.91 EPS (vs. $2.81 est.) and $5.25B revenue (vs. $5.15B est.), issued FY2026 EPS guidance of 12.35–12.65, and currently has a consensus analyst rating of Hold with a $195.46 target.
• The company authorized a $10 million share repurchase program and declared a quarterly dividend of $1.05 per share (annualized $4.20; yield ~2.6%).

Quadrant Capital Group LLC raised its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 152.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,724 shares of the medical instruments supplier's stock after buying an additional 9,491 shares during the quarter. Quadrant Capital Group LLC's holdings in Becton, Dickinson and Company were worth $2,943,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. SOA Wealth Advisors LLC. boosted its position in shares of Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 95 shares during the last quarter. Activest Wealth Management increased its position in Becton, Dickinson and Company by 285.3% in the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 97 shares during the last quarter. Bell Investment Advisors Inc increased its position in Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 128 shares during the last quarter. Cornerstone Planning Group LLC raised its stake in Becton, Dickinson and Company by 463.3% during the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 139 shares in the last quarter. Finally, Accredited Wealth Management LLC lifted its position in Becton, Dickinson and Company by 77.8% during the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 70 shares during the last quarter. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $163.22 on Thursday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock has a market cap of $46.47 billion, a price-to-earnings ratio of 26.63, a price-to-earnings-growth ratio of 11.88 and a beta of 0.24. The firm has a 50-day moving average of $191.41 and a two-hundred day moving average of $190.50. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. During the same period last year, the business posted $3.43 EPS. Becton, Dickinson and Company's quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company announced that its board has authorized a stock repurchase program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares buyback programs are often an indication that the company's management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.6%. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 68.52%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the transaction, the director owned 36,763 shares in the company, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,416 shares of company stock worth $674,693 in the last ninety days. Insiders own 0.40% of the company's stock.

Analysts Set New Price Targets

BDX has been the topic of a number of research reports. Piper Sandler restated a "neutral" rating and issued a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Zacks Research downgraded shares of Becton, Dickinson and Company from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 11th. Stifel Nicolaus boosted their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a "buy" rating in a research note on Wednesday, January 7th. TD Cowen upped their price objective on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a "hold" rating in a research report on Wednesday, February 11th. Finally, Morgan Stanley raised their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an "overweight" rating in a research note on Tuesday, December 2nd. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $195.46.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.